[Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program].
Fourcade
Richard-Olivier
RO
Centre Hospitalier, Auxerre.
Richaud
Pierre
P
Coloby
Patrick
P
Malavaud
Bernard
B
D000465:Algorithms; D000813:Anilides / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009570:Nitriles / Q000008:administration & dosage*; D015397:Program Evaluation; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D014105:Tosyl Compounds / Q000008:administration & dosage*
D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide